NURS 6521N WEEK 9 QUIZ 2.Q&A

NURS 6521N WEEK 9 QUIZ 2.Q&A QUESTION 1 1. A nurse is discussing oprelvekin therapy with a male patient. Which of the following will the nurse tell the patient is the most common adverse effect of the drug? A. Medu ...

NURS 6521N WEEK 9 QUIZ 2.Q&A QUESTION 1 1. A nurse is discussing oprelvekin therapy with a male patient. Which of the following will the nurse tell the patient is the most common adverse effect of the drug? A. Medullary bone pain B. Fluid retention/weight gain C. Atrial arrhythmia D. Papilledema 1 points QUESTION 2 1. A patient has been scheduled to begin treatment with rituximab for non-Hodgkin's lymphoma. The nurse who will administer this drug should understand that it targets A. specific antigens on the surface of malignant B cells. B. the molecular structure of the cells making up the semipermeable membrane of cancerous cells. C. the function of the complement system. D. the DNA of mature plasma cells. 1 points QUESTION 3 1. A patient with a diagnosis of chronic myeloid leukemia has met with her oncologist, who has recommended treatment with the kinase inhibitor imatinib. What route of administration should the nurse explain to the patient? A. Weekly IV infusions over 6 to 8 hours through a central line B. Peripheral IV administration three times a day for 7 to 10 days C. Daily intramuscular injections throughout the course of treatment D. Oral administration of imatinib in a home setting 1 points QUESTION 4 1. A female patient is prescribed oprelvekin therapy to treat thrombocytopenia. Which of the following should the nurse continuously monitor to determine the efficacy and duration of the oprelvekin therapy? A. Weight gain B. Red and white blood cell count C. Cardiac arrhythmias D. Platelet count 1 points QUESTION 5 1. A nurse has been assigned to a female patient who is to begin chemotherapy. The nurse will initiate the prescribed oprelvekin therapy A. 6 days after chemotherapy. B. 6 to 24 hours after chemotherapy. C. 2 days after chemotherapy. D. 10 days after chemotherapy. 1 points QUESTION 6 1. A middle-aged patient has received a diagnosis of GI stromal tumor following an extensive diagnostic workup. Imatinib has been recommended as a component of the patient's drug regimen. What patient education should the nurse provide to this patient? A. “It's important that you let us know if you develop any significant swelling or puffiness.” B. “Try to keep your PICC line dressing as dry as possible at all times.” C. “If you experience significant nausea after taking a dose, stop taking the drug and schedule an appointment at the clinic.” D. “You'll likely experience a lot of dry mouth while you're taking this drug, so it's helpful to chew ice chips.” 1 points QUESTION 7 1. An oncology nurse is aware of the risks for injury that exist around the preparation, transportation, and administration of chemotherapeutic agents. In order to reduce these risks of injury, the nurse should take which of the following actions? A. Use an IV system for administration that includes needles to reduce the risk of accidental spills. B. Dispose of intravenous lines used for chemotherapy administration in a covered trash can in the patient's room. C. Encourage patients who have been receiving chemotherapy to use a bedside commode rather than a toilet. D. Prime the IV tubing with an approved IV solution rather than with the drug itself. 1 points QUESTION 8 1. A nurse on an oncology unit is aware of the need to assess for adverse effects in patients who are being treated with rituximab. The risks of adverse effects are highest at what point during the course of treatment. A. At each point that the dosage of rituximab is increased B. After 6 to 8 weeks of treatment at the maximum dose C. Shortly after the initiation of the first infusion of rituximab D. 48 to 72 hours after the first dose has been administered 1 points QUESTION 9 1. A patient with a recent diagnosis of chronic myelogenous leukemia (CML) is discussing treatment options with his care team. What aspect of the patient's condition would contraindicate the use of cyclophosphamide for the treatment of leukemia? A. The patient's bone marrow function is significantly depressed. B. The patient has had a history of nonadherence to medical treatment. C. The patient has decreased renal function. D. The patient has a diagnosis of type 2 diabetes and takes oral antihyperglycemics. 1 points QUESTION 10 1. A 60-year-old patient experienced a sudden onset of chest pain and shortness of breath and was subsequently diagnosed with a pulmonary embolism in the emergency department. The patient has been started on an intravenous heparin infusion. How does this drug achieve therapeutic effect? A. By promoting the rapid excretion of vitamin K by the gastrointestinal mucosa B. By inactivating clotting factors and thus stopping the coagulation cascade C. By inhibiting the action of vitamin K at its sites of action D. By inhibiting platelet aggregation on vessel walls and promoting fibrinolysis .........CONTINUED